Previous 10 | Next 10 |
Sonde extends use of its voice-based health detection and monitoring platform beyond respiratory illness to cognitive and mental health conditions PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stag...
Shionogi successfully completes first-ever clinical study of Akili’s video game-based cognitive treatment outside of the U.S.; plans to advance technology to the next step Data show Akili’s digital treatment was well-received and improved inattention in children ...
Dysfunction of the mesenteric lymphatics and leakage of pro-inflammatory lymph fluids promoted the accumulation of visceral adipose tissue and insulin resistance in a preclinical model Treatment with a lymph-targeted COX-2 inhibitor using PureTech’s Glyph TM technol...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that G...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Vor Biopharma (Nasdaq: VOR) (“Vor”) announced that the U.S. Food and Drug Admi...
Strong capital base and cash runway expected into the first quarter of 2025, with PureTech level cash and cash equivalents of $409.7 million 1 and consolidated cash and cash equivalents of $439.8 million 2 as of June 30, 2021 Continued advancement of PureTech’s ...
LYT-100 was well-tolerated when given twice-daily over multiple ascending doses with no maximum tolerated dose observed Results demonstrated dose-proportional PK profile and a modest food effect LYT-100 is currently being evaluated in two Phase 2 trials in patients wit...
Akili to license TALi’s technology for use in the U.S. as part of the agreement PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company today announced that its Founded Entit...
Industry veteran and board-certified physician to oversee advancement of PureTech’s clinical-stage Wholly Owned Pipeline PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics compa...
Imbrium Therapeutics has paid PureTech $6.5 million and PureTech is eligible to receive up to $53 million in additional development milestone payments for this program in addition to royalties on product sales Imbrium is responsible for all future development activities and fu...
News, Short Squeeze, Breakout and More Instantly...
Appointments support ongoing Phase 2 COLLECTiVE202 trial of VE202, pivotal Phase 3 RESTORATiVE303 trial of VE303 and planning for commercial stage activity PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated...
2024-06-27 14:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, confirms that the Tender Offer announced by the Company on 20 May 2024 is now ...